간행물

생화학분자생물학회입니다.


BmB Reports

Identification and structure of AIMP2-DX2 for therapeutic perspectives

  • 작성자

    Se Bok Jang
  • 작성일자

    2024-07-22
  • 조회수

    863
Name: Se Bok Jang ( sbjang@pusan.ac.kr )
2011-presentProfessor, Department of Molecular Biology, Pusan National University
2002-2010Assistant and Associate Professor, Department of Molecular Biology and Korea Nanobiotechnology Center, Pusan National University
2000-2002Research Assistant Professor, Department of Life Sciences, POSTECH
1996-2000Postdoctoral research fellow, University of California, Berkeley and Utah State University, USA
1992-1995Ph.D., Department of Chemistry, Pusan National University.

Identification and structure of AIMP2-DX2 for therapeutic perspectives

Regulation of cell fate and lung cell differentiation is associated with Aminoacyl-tRNA synthetases (ARS)-interacting multifunctional protein 2 (AIMP2), which acts as a non-enzymatic component required for the multi-tRNA synthetase complex. In response to DNA damage, a component of AIMP2 separates from the multi-tRNA synthetase complex, binds to p53, and prevents its degradation by MDM2, inducing apoptosis. Additionally, AIMP2 reduces proliferation in TGF-β and Wnt pathways, while enhancing apoptotic signaling induced by tumor necrosis fac- tor-α. Given the crucial role of these pathways in tumorigenesis, AIMP2 is expected to function as a broad-spectrum tumor suppressor. The full-length AIMP2 transcript consists of four exons, with a small section of the pre-mRNA undergoing alter- native splicing to produce a variant (AIMP2-DX2) lacking the second exon. AIMP2-DX2 binds to FBP, TRAF2, and p53 similarly to AIMP2, but competes with AIMP2 for binding to these target proteins, thereby impairing its tumor-suppressive activity. AIMP2-DX2 is specifically expressed in a diverse range of cancer cells, including breast cancer, liver cancer, bone cancer, and stomach cancer. There is growing interest in AIMP2-DX2 as a promising biomarker for prognosis and diagnosis, with AIMP2-DX2 inhibition attracting significant interest as a potentially effective therapeutic approach for the treatment of lung, ovarian, prostate, and nasopharyngeal cancers.


BMB Rep. 2024 Jun 5:6233. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38835119/